UC San Francisco has launched the Baszucki Lymphoma Therapeutics Initiative to increase the effectiveness and availability of chimeric antigen receptor T-cell (CAR T) therapy for lymphoma patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results